Luuk B Hilbrands

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4758555/publications.pdf

Version: 2024-02-01

195 papers 7,171 citations

43 h-index 75 g-index

202 all docs 202 docs citations

202 times ranked 9415 citing authors

#	Article	IF	Citations
1	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Clinical Infectious Diseases, 2023, 76, e188-e199.	5.8	24
2	Artificial intelligence: is there a potential role in nephropathology?. Nephrology Dialysis Transplantation, 2022, 37, 438-440.	0.7	4
3	Hyperhydration with cisplatin does not influence pemetrexed exposure. British Journal of Clinical Pharmacology, 2022, 88, 871-876.	2.4	2
4	Assessment of pre-donation glomerular filtration rate: going back to basics. Nephrology Dialysis Transplantation, 2022, 37, 430-437.	0.7	7
5	Kidney Transplantation After Rescue Allocation—the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis. Transplantation, 2022, 106, 1215-1226.	1.0	7
6	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. Transplantation, 2022, 106, 821-834.	1.0	127
7	Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA. Nephrology Dialysis Transplantation, 2022, 37, 1140-1151.	0.7	7
8	Association of obesity with 3-month mortality in kidney failure patients with COVID-19. CKJ: Clinical Kidney Journal, 2022, 15, 1348-1360.	2.9	2
9	Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19. Transplantation, 2022, 106, 1012-1023.	1.0	8
10	Combining transplant professional's psychosocial donor evaluation and donor self-report measures to optimise the prediction of HRQoL after kidney donation: an observational prospective multicentre study. BMJ Open, 2022, 12, e045249.	1.9	1
11	"What matters to you?― The relevance of patient priorities in dialysis care for assessment and clinical practice. Seminars in Dialysis, 2022, , .	1.3	3
12	A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients. Clinical and Translational Science, 2022, 15, 930-941.	3.1	7
13	Microparticles in Autoimmunity: Cause or Consequence of Disease?. Frontiers in Immunology, 2022, 13, 822995.	4.8	6
14	MO337: Higher Antibody Response After 2 Vaccinations With MRNA-1273 as Compared With BNT162B2 and AZD1222 in High-Risk Kidney Patients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
15	Dialysis or kidney transplantation in older adults? A systematic review summarizing functional, psychological, and quality of life-related outcomes after start of kidney replacement therapy. International Urology and Nephrology, 2022, 54, 2891-2900.	1.4	5
16	MO495: A Comparative Study of Patient Mortality During First and Second Waves of Covid-19 Pandemic in Dialysis Patients and Kidney Transplant Recipients. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
17	Kidney transplantation or dialysis in older adults—an interview study on the decision-making process. Age and Ageing, 2022, 51, .	1.6	6
18	MO899: The Clinical frailty Scale is Useful for ICU Triage in Dialysis Patients With COVID-19–An Eracoda Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0

#	Article	IF	CITATIONS
19	COVID-19 pandemic waves and mortality among patients on kidney replacement therapy. Kidney International Reports, 2022, , .	0.8	6
20	Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group. Nephrology Dialysis Transplantation, 2022, 37, 1824-1829.	0.7	6
21	Employment and ability to work after kidney transplantation in the Netherlands: The impact of preemptive versus nonâ€preemptive kidney transplantation. Clinical Transplantation, 2022, 36, .	1.6	4
22	E-HEalth treatment in Long-term Dialysis (E-HELD): study protocol for a multicenter randomized controlled trial evaluating personalized Internet-based cognitive-behavioral therapy in dialysis patients. Trials, 2022, 23, .	1.6	5
23	Convolutional Neural Networks for the Evaluation of Chronic and Inflammatory Lesions in Kidney Transplant Biopsies. American Journal of Pathology, 2022, 192, 1418-1432.	3.8	16
24	Predicting health-related quality of life in dialysis patients: Factors related to negative outcome expectancies and social support. Patient Education and Counseling, 2021, 104, 1474-1480.	2.2	7
25	Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrology Dialysis Transplantation, 2021, 36, 87-94.	0.7	259
26	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. Clinical Pharmacokinetics, 2021, 60, 649-654.	3.5	7
27	Pitfalls when comparing COVID-19-related outcomes across studies—lessons learnt from the ERACODA collaboration. CKJ: Clinical Kidney Journal, 2021, 14, i14-i20.	2.9	7
28	Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups. Nephrology Dialysis Transplantation, 2021, 36, 1742-1753.	0.7	13
29	Reduced CXCL1 production by endogenous IL-37 expressing dendritic cells does not affect T cell activation. PLoS ONE, 2021, 16, e0251809.	2.5	0
30	Quantitative assessment of inflammatory infiltrates in kidney transplant biopsies using multiplex tyramide signal amplification and deep learning. Laboratory Investigation, 2021, 101, 970-982.	3.7	25
31	The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant. Nephrology Dialysis Transplantation, 2021, 36, 1761-1764.	0.7	33
32	Delayed graft function and rejection are risk factors for cytomegalovirus breakthrough infection in kidney transplant recipients. Pharmacological Research, 2021, 167, 105565.	7.1	7
33	COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study. Nephrology Dialysis Transplantation, 2021, 36, 2094-2105.	0.7	65
34	A Combined microRNA and Chemokine Profile in Urine to Identify Rejection After Kidney Transplantation. Transplantation Direct, 2021, 7, e711.	1.6	6
35	Clinical triage of patients on kidney replacement therapy presenting with COVID-19: an ERACODA registry analysis. Nephrology Dialysis Transplantation, 2021, 36, 2308-2320.	0.7	3
36	Implementation of the kidney team at home intervention: Evaluating generalizability, implementation process, and effects. Transplant International, 2021, 34, 2317-2328.	1.6	6

3

#	Article	lF	CITATIONS
37	T-Cell Epitopes Shared Between Immunizing HLA and Donor HLA Associate With Graft Failure After Kidney Transplantation. Frontiers in Immunology, 2021, 12, 784040.	4.8	8
38	Latest developments in living kidney donation. Current Opinion in Organ Transplantation, 2020, 25, 74-79.	1.6	9
39	Increased Plasma Heparanase Activity in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 575047.	4.8	98
40	Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomised, double-blind, paired, phase 3 trial. Lancet, The, 2020, 396, 1653-1662.	13.7	109
41	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. Cell Reports Medicine, 2020, 1, 100146.	6.5	24
42	COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology Dialysis Transplantation, 2020, 35, 1973-1983.	0.7	312
43	Role of syndecan-1 in the interaction between dendritic cells and T cells. PLoS ONE, 2020, 15, e0230835.	2.5	6
44	Immunosuppressive Drugs and COVID-19: A Review. Frontiers in Pharmacology, 2020, 11, 1333.	3.5	89
45	Histopathological examination of removed kidney allografts: Is it useful? A retrospective cohort study. Transplant International, 2020, 33, 1693-1699.	1.6	0
46	The clinical characteristics of coronavirus-associated nephropathy. Nephrology Dialysis Transplantation, 2020, 35, 1279-1281.	0.7	14
47	CKD is a key risk factor for COVID-19 mortality. Nature Reviews Nephrology, 2020, 16, 705-706.	9.6	151
48	Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer, 2020, 146, 30-35.	2.0	20
49	How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. Nephrology Dialysis Transplantation, 2020, 35, 899-904.	0.7	96
50	ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19. Nephrology Dialysis Transplantation, 2020, 35, 2023-2025.	0.7	25
51	Double J stent is superior to externally draining ureteric stent in enhancing recovery after kidney transplantation $\hat{a} \in A$ prospective cohort study. International Journal of Surgery, 2019, 71, 175-181.	2.7	7
52	Standard work-up of the low-risk kidney transplant candidate: a European expert survey of the ERA-EDTA Developing Education Science and Care for Renal Transplantation in European States Working Group. Nephrology Dialysis Transplantation, 2019, 34, 1605-1611.	0.7	12
53	Deep Learning–Based Histopathologic Assessment of Kidney Tissue. Journal of the American Society of Nephrology: JASN, 2019, 30, 1968-1979.	6.1	226
54	Are cell-based therapies for kidney disease safe? A systematic review of preclinical evidence. , 2019, 197, 191-211.		8

#	Article	IF	CITATIONS
55	Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients. American Journal of Transplantation, 2019, 19, 2926-2933.	4.7	32
56	Antibodies against ARHGDIB are associated with long-term kidney graft loss. American Journal of Transplantation, 2019, 19, 3335-3344.	4.7	46
57	Pre-existing malignancies in renal transplant candidates—time to reconsider waiting times. Nephrology Dialysis Transplantation, 2019, 34, 1292-1300.	0.7	15
58	Efficacy of profound versus moderate neuromuscular blockade in enhancing postoperative recovery after laparoscopic donor nephrectomy. European Journal of Anaesthesiology, 2019, 36, 494-501.	1.7	15
59	Toward a Sensible Single-antigen Bead Cutoff Based on Kidney Graft Survival. Transplantation, 2019, 103, 789-797.	1.0	31
60	Effect of initial immunosuppression on long-term kidney transplant outcome in immunological low-risk patients. Nephrology Dialysis Transplantation, 2019, 34, 1417-1422.	0.7	7
61	Psychosocial consequences of living kidney donation: a prospective multicentre study on health-related quality of life, donor–recipient relationships and regret. Nephrology Dialysis Transplantation, 2019, 34, 1045-1055.	0.7	24
62	Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients. Transplantation Reviews, 2019, 33, 55-63.	2.9	18
63	A paired kidney analysis on the impact of pre-transplant anti-HLA antibodies on graft survival. Nephrology Dialysis Transplantation, 2019, 34, 1056-1063.	0.7	17
64	Prolonged Duration of Brain Death was Associated with Better Kidney Allograft Function and Survival: A Prospective Cohort Analysis. Annals of Transplantation, 2019, 24, 147-154.	0.9	10
65	Safety evaluation of conditionally immortalized cells for renal replacement therapy. Oncotarget, 2019, 10, 5332-5348.	1.8	6
66	Prediction models for delayed graft function: external validation on The Dutch Prospective Renal Transplantation Registry. Nephrology Dialysis Transplantation, 2018, 33, 1259-1268.	0.7	21
67	Differential effects of donor-specific HLA antibodies in living versus deceased donor transplant. American Journal of Transplantation, 2018, 18, 2274-2284.	4.7	65
68	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.7	32
69	Review: Management of patients with kidney allograft failure. Transplantation Reviews, 2018, 32, 178-186.	2.9	17
70	Graft intolerance syndrome requiring graft nephrectomy after late kidney graft failure: can it be predicted? A retrospective cohort study. Transplant International, 2018, 31, 220-229.	1.6	15
71	Prevalence and Impact of Chronic Postsurgical Pain Following Laparoscopic Donor Nephrectomy. Transplantation, 2018, 102, S43.	1.0	0
72	Double J is Superior to Externally Draining Ureteric Stent in Enhancing Recovery After Living Donor Kidney Transplantation. Transplantation, 2018, 102, S497-S498.	1.0	1

#	Article	IF	Citations
73	Development and Validation of a Multiplex Non-HLA Antibody Assay for the Screening of Kidney Transplant Recipients. Frontiers in Immunology, 2018, 9, 3002.	4.8	25
74	FOO48EFFECT OF INITIAL IMMUNOSUPPRESSION ON LONG TERM KIDNEY TRANSPLANT OUTCOME IN IMMUNOLOGICAL LOW RISK PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i39-i39.	0.7	2
75	Equivalent Long-term Transplantation Outcomes for Kidneys Donated After Brain Death and Cardiac Death: Conclusions From a Nationwide Evaluation. EClinicalMedicine, 2018, 4-5, 25-31.	7.1	44
76	Development and feasibility of a guided and tailored internet-based cognitive-behavioural intervention for kidney donors and kidney donor candidates. BMJ Open, 2018, 8, e020906.	1.9	7
77	Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure. Journal of the American Society of Nephrology: JASN, 2018, 29, 2279-2285.	6.1	25
78	PIRCHE-II Is Related to Graft Failure after Kidney Transplantation. Frontiers in Immunology, 2018, 9, 321.	4.8	63
79	Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation. Annals of the Rheumatic Diseases, 2018, 77, 1790-1798.	0.9	86
80	Automatic segmentation of histopathological slides of renal tissue using deep learning. , 2018, , .		23
81	Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients. American Journal of Transplantation, 2017, 17, 2372-2380.	4.7	60
82	Effectiveness of deep versus moderate muscle relaxation during laparoscopic donor nephrectomy in enhancing postoperative recovery: study protocol for a randomized controlled study. Trials, 2017, 18, 99.	1.6	2
83	Neutrophil Extracellular Traps Drive Endothelial-to-Mesenchymal Transition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1371-1379.	2.4	176
84	Quality of Recovery After Lowâ€Pressure Laparoscopic Donor Nephrectomy Facilitated by Deep Neuromuscular Blockade: A Randomized Controlled Study. World Journal of Surgery, 2017, 41, 2950-2958.	1.6	31
85	Similar 5-Year Estimated Glomerular Filtration Rate Between Kidney Transplants From Uncontrolled and Controlled Donors After Circulatory Deathâ€"A Dutch Cohort Study. Transplantation, 2017, 101, 1144-1151.	1.0	23
86	Pretransplant Numbers of CD16 + Monocytes as a Novel Biomarker to Predict Acute Rejection After Kidney Transplantation: A Pilot Study. American Journal of Transplantation, 2017, 17, 2659-2667.	4.7	29
87	Pre-donation cognitions of potential living organ donors: the development of the Donation Cognition Instrument in potential kidney donors. Nephrology Dialysis Transplantation, 2017, 32, 573-580.	0.7	9
88	Long-term risks of kidney living donation: review and position paper by the ERA-EDTA DESCARTES working group. Nephrology Dialysis Transplantation, 2017, 32, 216-223.	0.7	79
89	Reactivation of Latent HPV Infections After Renal Transplantation. American Journal of Transplantation, 2017, 17, 1563-1573.	4.7	44
90	OR41 PIRCHE-II: A novel tool to identify permissible HLA mismatches in kidney transplantation. Human Immunology, 2017, 78, 39.	2.4	1

#	Article	IF	CITATIONS
91	Allostimulatory capacity of conditionally immortalized proximal tubule cell lines for bioartificial kidney application. Scientific Reports, 2017, 7, 7103.	3.3	18
92	Improvement of Gynecological Screening of Female Renal Transplant Recipients by Self-Sampling for Human Papillomavirus Detection. Journal of Lower Genital Tract Disease, 2017, 21, 33-36.	1.9	2
93	Pretransplant Numbers of CD16+ Monocytes as a Novel Biomarker to Predict Acute Rejection after Kidney Transplantation. Transplantation, 2017, 101, S40.	1.0	0
94	Absence of Intragraft B Cells in Rejection Biopsies After Rituximab Induction Therapy: Consequences for Clinical Outcome. Transplantation Direct, 2017, 3, e143.	1.6	10
95	Urinary MicroRNA as Biomarker in Renal Transplantation. American Journal of Transplantation, 2017, 17, 1160-1166.	4.7	29
96	Increased risk of graft failure and mortality in Dutch recipients receiving an expanded criteria donor kidney transplant. Transplant International, 2017, 30, 14-28.	1.6	17
97	Stretching the Limits of Renal Transplantation in Elderly Recipients of Grafts from Elderly Deceased Donors. Journal of the American Society of Nephrology: JASN, 2017, 28, 621-631.	6.1	63
98	Role of Vitamin D in Maintaining Renal Epithelial Barrier Function in Uremic Conditions. International Journal of Molecular Sciences, 2017, 18, 2531.	4.1	23
99	Acetylated Histones in Apoptotic Microparticles Drive the Formation of Neutrophil Extracellular Traps in Active Lupus Nephritis. Frontiers in Immunology, 2017, 8, 1136.	4.8	76
100	Human Alpha-1-Antitrypsin (hAAT) therapy reduces renal dysfunction and acute tubular necrosis in a murine model of bilateral kidney ischemia-reperfusion injury. PLoS ONE, 2017, 12, e0168981.	2. 5	21
101	NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors and predicts thiazide sensitivity. PLoS ONE, 2017, 12, e0176220.	2.5	30
102	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. Nephrology Dialysis Transplantation, 2017, 32, 402-402.	0.7	3
103	Neutrophils Discriminate between Lipopolysaccharides of Different Bacterial Sources and Selectively Release Neutrophil Extracellular Traps. Frontiers in Immunology, 2016, 7, 484.	4.8	181
104	Allostimulatory Effects of Dendritic Cells with Characteristic Features of a Regulatory Phenotype. PLoS ONE, 2016, 11, e0159986.	2.5	6
105	Predominant Tubular Interleukin-18 Expression in Polyomavirus-Associated Nephropathy. Transplantation, 2016, 100, e88-e95.	1.0	16
106	The Dutch Transplantation in Vasculitis (DUTRAVAS) Study. Transplantation, 2016, 100, 916-924.	1.0	29
107	Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. Arthritis and Rheumatology, 2016, 68, 462-472.	5.6	131
108	How can we reduce costs of solidâ€phase multiplexâ€bead assays used to determine antiâ€ <scp>HLA</scp> antibodies?. Hla, 2016, 88, 110-119.	0.6	15

#	Article	IF	Citations
109	Epidemiology and management of hypertension in paediatric and young adult kidney transplant recipients in The Netherlands. Nephrology Dialysis Transplantation, 2016, 31, 1947-1956.	0.7	15
110	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrology Dialysis Transplantation, 2016, 31, 1515-1522.	0.7	14
111	Nighttime kidney transplantation is associated with less pure technical graft failure. World Journal of Urology, 2016, 34, 955-961.	2.2	18
112	Intragraft Blood Dendritic Cell Antigen-1–Positive Myeloid Dendritic Cells Increase during BK Polyomavirus–Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 2502-2510.	6.1	10
113	Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis. PLoS ONE, 2016, 11, e0165373.	2.5	60
114	Delayed trough level measurement with the use of prolonged-release tacrolimus. Transplant International, 2015, 28, 314-318.	1.6	8
115	Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations. Scientific Reports, 2015, 5, 16702.	3.3	90
116	Comparison of the effectiveness of low pressure pneumoperitoneum with profound muscle relaxation during laparoscopic donor nephrectomy to optimize the quality of recovery during the early post-operative phase: study protocol for a randomized controlled clinical trial. Trials, 2015, 16, 345.	1.6	7
117	Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. Arthritis Research and Therapy, 2015, 17, 103.	3.5	23
118	KIR and Human Leukocyte Antigen Genotype Associated Risk of Cytomegalovirus Disease in Renal Transplant Patients. Transplantation, 2015, 99, 1506-1513.	1.0	10
119	The Course and Predictors of Health-Related Quality of Life in Living Kidney Donors: A Systematic Review and Meta-Analysis. American Journal of Transplantation, 2015, 15, 3041-3054.	4.7	58
120	Cytokine Release After Treatment With Rituximab in Renal Transplant Recipients. Transplantation, 2015, 99, 1907-1911.	1.0	11
121	Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation. Transplant Immunology, 2015, 32, 18-22.	1.2	18
122	Anti-B cell therapy with rituximab as induction therapy in renal transplantation. Transplant Immunology, 2014, 31, 207-209.	1.2	6
123	On the occasion of the 25th anniversary of the Dutch Transplantation Society. Transplant Immunology, 2014, 31, 183.	1.2	0
124	The interplay between antiviral immunity and allo-immune reactivity after renal transplantation. Transplant Immunology, 2014, 31, 191-194.	1.2	2
125	15-Year Follow-up of a Multicenter, Randomized, Calcineurin Inhibitor Withdrawal Study in Kidney Transplantation. Transplantation, 2014, 98, 47-53.	1.0	41
126	Effect of Long-term Storage of Urine Samples on Measurement of Kidney Injury Molecule 1 (KIM-1) and Neutrophil Gelatinase-Associated Lipocalin (NGAL). American Journal of Kidney Diseases, 2014, 63, 573-576.	1.9	32

#	Article	IF	CITATIONS
127	Longitudinal Analysis of T and B Cell Phenotype and Function in Renal Transplant Recipients with or without Rituximab Induction Therapy. PLoS ONE, 2014, 9, e112658.	2.5	39
128	CD19 Is a Useful B Cell Marker After Treatment With Rituximab: Comment on the Article by Jones et al. Arthritis and Rheumatism, 2013, 65, 1130-1131.	6.7	9
129	The effects of in vivo B-cell depleting therapy on ex-vivo cytokine production. Transplant Immunology, 2013, 28, 183-188.	1.2	4
130	Treatment Satisfaction in Renal Transplant Patients Taking Tacrolimus Once Daily. Clinical Therapeutics, 2013, 35, 1821-1829.e1.	2.5	31
131	Treatment of Steroid-Resistant Acute Renal Allograft Rejection With Alemtuzumab. American Journal of Transplantation, 2013, 13, 192-196.	4.7	35
132	A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function. American Journal of Transplantation, 2013, 13, 1503-1511.	4.7	126
133	Effect of a Single Intraoperative High-Dose ATG-Fresenius on Delayed Graft Function in Donation After Cardiac-Death Donor Renal Allograft Recipients: A Randomized Study. Experimental and Clinical Transplantation, 2013, 11, 134-141.	0.5	14
134	Insulin Requirement After a Renal Transplant in Patients With Type 2 Diabetes: The Choice of Calcineurin Inhibitors. Experimental and Clinical Transplantation, 2013, 11, 234-238.	0.5	3
135	Effect of Mild Diarrhea on Tacrolimus Exposure. Transplantation, 2012, 94, 763-767.	1.0	15
136	Effect of administration of apoptotic blebs on disease development in lupus mice. Autoimmunity, 2012, 45, 290-297.	2.6	10
137	Anti-T-cell antibodies for the treatment of acute rejection after renal transplantation. Expert Opinion on Biological Therapy, 2012, 12, 1031-1042.	3.1	20
138	In Vitro Effects of Rituximab on the Proliferation, Activation and Differentiation of Human B Cells. American Journal of Transplantation, 2012, 12, 341-350.	4.7	35
139	Current perspectives to overcome a positive crossmatch in living donor renal transplantation*. Transplant International, 2012, 25, 503-505.	1.6	0
140	What to do with a failed renal allograft: take it or leave it?. Transplant International, 2011, 24, e54-e54.	1.6	0
141	Synchronized turbo apoptosis induced by cold-shock. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 86-93.	4.9	13
142	Nephrotic syndrome induced by pamidronate. Medical Oncology, 2011, 28, 1196-1200.	2.5	12
143	Use of monoclonal antibodies in renal transplantation. Immunotherapy, 2011, 3, 871-880.	2.0	39
144	Single-Dose Rituximab as Induction in Renal Transplantation. Transplantation, 2010, 89, 1295.	1.0	0

#	Article	IF	Citations
145	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	7.0	212
146	The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Research and Therapy, 2010, 12, 207.	3.5	80
147	Immunotherapy with regulatory T cells in transplantation. Immunotherapy, 2009, 1, 855-871.	2.0	11
148	Urinary Albumin–Total Protein Ratio: A New Diagnostic Tool to Differentiate Glomerular From Nonglomerular Hematuria?. American Journal of Kidney Diseases, 2009, 53, 180.	1.9	0
149	Mouse dendritic cells matured by ingestion of apoptotic blebs induce T cells to produce interleukinâ€17. Arthritis and Rheumatism, 2009, 60, 2304-2313.	6.7	85
150	Use of the Platelet Function Analyzer to minimize bleeding complications after renal biopsy. Thrombosis Research, 2009, 123, 515-522.	1.7	11
151	Both early and late apoptotic blebs are taken up by DC and induce IL-6 production. Autoimmunity, 2009, 42, 325-327.	2.6	27
152	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2009, 31, 585-591.	2.0	27
153	Causes of frequency and nocturia after renal transplantation. BJU International, 2008, 101, 1029-1034.	2.5	16
154	Population Pharmacokinetics of Mycophenolic Acid. Clinical Pharmacokinetics, 2008, 47, 827-838.	3.5	79
155	Ex Vivo Generation of Human Alloantigen-Specific Regulatory T Cells from CD4posCD25high T Cells for Immunotherapy. PLoS ONE, 2008, 3, e2233.	2.5	82
156	Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus. PLoS ONE, 2008, 3, e2711.	2.5	44
157	Clinical Grade Treg: GMP Isolation, Improvement of Purity by CD127pos Depletion, Treg Expansion, and Treg Cryopreservation. PLoS ONE, 2008, 3, e3161.	2.5	105
158	The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25â^' T cells. Blood, 2007, 109, 244-252.	1.4	21
159	The Presence of Donor-Specific Human Leukocyte Antigen Antibodies Does Not Preclude Successful Withdrawal of Tacrolimus in Stable Renal Transplant Recipients. Transplantation, 2007, 84, 1092-1096.	1.0	5
160	KIR Gene and KIR Ligand Analysis to Predict Graft Rejection After Renal Transplantation. Transplantation, 2007, 84, 1045-1051.	1.0	23
161	Allogeneic stimulation of naturally occurring CD4+CD25+ T cells induces strong regulatory capacity with increased donor-reactivity. Transplant Immunology, 2007, 17, 237-242.	1.2	10
162	Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+CD25+FoxP3+ T cells. Bone Marrow Transplantation, 2007, 39, 537-545.	2.4	138

#	Article	IF	Citations
163	Following Anti-CD25 Treatment, A Functional CD4+CD25+ Regulatory T-Cell Pool Is Present in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 249-255.	4.7	79
164	Alternaria infectoriaphaeohyphomycosis in a renal transplant patient. Medical Mycology, 2006, 44, 379-382.	0.7	22
165	Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood, 2006, 107, 1018-1023.	1.4	230
166	Dendritic Cells Activated by Lipopolysaccharide after Dexamethasone Treatment Induce Donor-Specific Allograft Hyporesponsiveness. Transplantation, 2006, 81, 1451-1459.	1.0	62
167	Diagnostic approach in patients with asymptomatic haematuria: efficient or not?. International Journal of Clinical Practice, 2006, 60, 557-561.	1.7	10
168	Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression. Clinical Transplantation, 2006, 20, 659-664.	1.6	22
169	Sirolimus-Associated Heavy Proteinuria in a Renal Transplant Recipient: Evidence for a Tubular Mechanism. American Journal of Transplantation, 2006, 6, 429-433.	4.7	106
170	Ex vivo expansion of human CD4+CD25high regulatory T cells from transplant recipients permits functional analysis of small blood samples. Journal of Immunological Methods, 2006, 314, 103-113.	1.4	17
171	CTLA-4 Engagement and Regulatory CD4+CD25+T Cells Independently Control CD8+-Mediated Responses under Costimulation Blockade. Journal of Immunology, 2006, 176, 5240-5246.	0.8	15
172	Tolerizing Effects of Co-stimulation Blockade Rest on Functional Dominance of CD4+CD25+ Regulatory T Cells. Transplantation, 2005, 79, 147-156.	1.0	22
173	Screening for microalbuminuria. Kidney International, 2005, 68, 1899-1900.	5.2	0
174	The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1stÂyear after renal transplantation. Osteoporosis International, 2005, 16, 255-262.	3.1	15
175	Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection. New England Journal of Medicine, 2005, 352, 2027-2028.	27.0	17
176	Screening for microalbuminuria. Kidney International, 2005, 68, 1899-1901.	5. 2	0
177	Steroid-Withdrawal at 3 Days After Renal Transplantation with Anti-IL-2 Receptor alpha Therapy: A Prospective, Randomized, Multicenter Study. American Journal of Transplantation, 2004, 4, 803-810.	4.7	119
178	Conversion from Cyclosporine to Tacrolimus Improves Quality-of-Life Indices, Renal Graft Function and Cardiovascular Risk Profile. American Journal of Transplantation, 2004, 4, 937-945.	4.7	134
179	Conversion from Cyclosporine to Tacrolimus Improves Quality of Life Indices, Renal Graft Function and Cardiovascular Risk Profile. American Journal of Transplantation, 2004, 4, 2140-2140.	4.7	0
180	Lower urinary tract symptoms after renal transplantation: are there changes over time?. Urology, 2004, 63, 442-446.	1.0	20

#	Article	IF	Citations
181	The fractional excretion of soluble interleukin-2 receptor-?? is an excellent predictor of the interleukin-2 receptor-?? status after treatment with daclizumab. Transplantation, 2004, 77, 281-286.	1.0	8
182	Dose Study of Thymoglobulin During Conditioning for Unrelated Donor Allogeneic Stem-Cell Transplantation. Transplantation, 2004, 78, 122-127.	1.0	153
183	Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrology Dialysis Transplantation, 2004, 19, 2852-2857.	0.7	58
184	Decreased renal excretion of soluble interleukin-2 receptor \hat{l}_{\pm} after treatment with daclizumab. Kidney International, 2003, 64, 697-703.	5.2	9
185	Permanent acceptance of both cardiac and skin allografts using a mild conditioning regimen for the induction of stable mixed chimerism in mice. Transplant Immunology, 2003, 11, 57-63.	1.2	3
186	Improved Cardiovascular Risk Profile and Renal Function in Renal Transplant Patients after Randomized Conversion from Cyclosporine to Tacrolimus. Journal of the American Society of Nephrology: JASN, 2003, 14, 1880-1888.	6.1	106
187	Is serum cystatin C the marker of choice to predict glomerular filtration rate in paediatric patients?. Annals of Clinical Biochemistry, 2003, 40, 60-64.	1.6	30
188	Withdrawal of Cyclosporine or Prednisone Six Months after Kidney Transplantation in Patients on Triple Drug Therapy. Journal of the American Society of Nephrology: JASN, 2002, 13, 1365-1373.	6.1	140
189	Elective withdrawal of mycophenolate mofetil in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone. Transplant International, 2001, 14, 99-102.	1.6	6
190	TWO DOSES OF DACLIZUMAB ARE SUFFICIENT FOR PROLONGED INTERLEUKIN-2R?? CHAIN BLOCKADE. Transplantation, 2001, 72, 1709.	1.0	21
191	Primary Epstein–Barr virus infection and recurrent type I membranoproliferative glomerulonephritis after renal transplantation. Nephrology Dialysis Transplantation, 2000, 15, 1235-1237.	0.7	7
192	The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrology Dialysis Transplantation, 2000, 15, 711-714.	0.7	97
193	Type I membranoproliferative glomerulonephritis in a renal allograft: A recurrence induced by a cytomegalovirus infection?. American Journal of Kidney Diseases, 2000, 35, e6.1-e6.7.	1.9	19
194	Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney International, 1991, 40, 1171-1176.	5.2	108
195	Surrogate Endpoints for Late Kidney Transplantation Failure. Transplant International, 0, 35, .	1.6	18